BioPharm International - May 2024

BioPharm International - May 2024

Issue link: https://www.e-digitaleditions.com/i/1520706

Contents of this Issue

Navigation

Page 21 of 21

BIOPHARMACEUTICAL ANALYTICAL DEVELOPMENT PROVEN EXPERTISE Your partner for regulatory-driven, phase-appropriate analytical programs tailored to your product. We offer Total Quality Assurance expertise, helping you to navigate the challenges of development, regulatory submission, and production. BIOLOGICS | CELL & GENE THERAPIES | OLIGONUCLEOTIDES | PHARMACEUTICALS • Experienced GLP/GCP and GMP laboratory services outsourcing partner • Global drug delivery expertise • Inhaled and nasal drug product development • Structural characterisation and physicochemical properties (ICH Q6B) • Clinical / preclinical bioanalysis (PK, ADA, Nab) and biomarker solutions • Method development / validation and GMP analysis • Comparability / biosimilar studies • ATMP analytical and CMC support • Cell based potency assays • ICH stability programs • Extractables / Leachables biopharma@intertek.com +44 (0)116 296 1620 intertek.com/pharmaceutical/biopharmaceuticals 3rd ANNUAL INHALED & NASAL BIOLOGICS/DNA FORUM 2024 26-27 SEPT | CAMBRIDGE, UK Join us for a ground-breaking and insightful forum on inhaled and nasal biologics development. Don't miss the opportunity to hear from world-renowned industry leaders sharing the latest learnings on inhaled & nasal biologics and DNA medicine development, including our keynote speaker, Dr Jenny Lam, Associate Professor in Pharmaceutics at the UCL School of Pharmacy, UK. Find out more online

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - May 2024 - BioPharm International - May 2024